Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2031-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate intermittent relugolix + androgen receptor pathway inhibitor (ARPI) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.